The Animal Models of Diabetic Complications Consortium (AMDCC) brings together a number of projects representing a diverse set of disciplines and technologies with the goal of improving or creating animal models of human diabetes complications.

The primary goal for this consortium is the creation of the animal models to study diabetes complication pathologies with an emphasis on the etiology, prevention and treatment of the disease. The secondary goal is to use these animal models to elucidate the role of specific genes or chromosomal regions in the pathogenesis of these complications.

The consortium consists of eight Mouse Engineering and Phenotyping units from different institutions and one Coordinating and Bioinformatics unit. Members of the AMDCC come from a diverse set of backgrounds with expertise in mouse genetic engineering technologies, organ pathologies, genomic technologies and diabetic complications.

Investigators focus their research efforts on a number of diabetic complications involving different organ systems and biochemical pathways. These complications include diabetic kidney disease, vascular disease, retinopathy, neuropathy and diabetic cardiomyopathy.

This complex research initiative will provide a valuable resource to the scientific community and will require the coordinated effort between the members of the consortium.

CONGRATULATIONS to OLIVER SMITHIES

The Nobel Assembly at Karolinska Institutet has today decided to award
The Nobel Prize in Physiology or Medicine for 2007 jointly to

Mario R. Capecchi, Martin J. Evans and Oliver Smithies

for their discoveries of "principles for introducing specific gene modifications in mice by the use of embryonic stem cells"

Summary

This year's Nobel Laureates have made a series of ground-breaking discoveries concerning embryonic stem cells and DNA recombination in mammals. Their discoveries led to the creation of an immensely powerful technology referred to as gene targeting in mice. It is now being applied to virtually all areas of biomedicine – from basic research to the development of new therapies.

The AMDCC would like to congratulate Dr. Smithies for this well deserved honor.

To see the entire press release click http://nobelprize.org/nobel_prizes/medicine/laureates/2007/press.html


NIDDK Request for Information:

Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Diabetic Complications in Rodent Models.

The NIDDK has recently awarded a contract establishing a rodent model testing program to assist in development of therapeutic interventions for the prevention or reversal of complications of type 1 diabetes. The contract provides independent investigators with access to the resources and expertise required to evaluate agents for preclinical therapeutic efficacy in rodent models. NIDDK invites scientists to submit information describing promising new therapeutics or intervention strategies that may require further testing in rodent models prior to moving forward for evaluation in patients with diabetic complications.

Visit Type 1 Diabetes Preclinical Testing Program (T1D-PTP) page or NIH Notice page for more information.

Click here for Tutorials and Frequently Asked Questions (FAQ)

	AMDCC Presentations Available The presentations for the semi-annual meetings are now available to the public. These include the invited speakers when available. All presentations are in PDF format to minimize spacre requirements. Just go to About AMDCC => Presentations or click here.

This site is best viewed with Netscape Navigator 6+ and Microsoft Internet Explorer 5.5+